Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc.
Your view on ELOX
Overview
What the company does, where it operates, and who runs it.
About Eloxx Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sumit Aggarwal
- Headquarters
- 480 Arsenal Way, Watertown, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sumit Aggarwal
- Headquarters
- 480 Arsenal Way, Watertown, MA, US
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.
Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Eloxx Pharmaceuticals, Inc., and the rating behind it. ELOX last traded at $15.75; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Eloxx Pharmaceuticals, Inc.. Starting points for Eloxx Pharmaceuticals, Inc.: EPS -$1.22, beta -9.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Eloxx Pharmaceuticals, Inc.. Eloxx Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Eloxx Pharmaceuticals, Inc.. Trailing twelve-month EPS for Eloxx Pharmaceuticals, Inc. stands at -$1.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Eloxx Pharmaceuticals, Inc.. Eloxx Pharmaceuticals, Inc. has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Eloxx Pharmaceuticals, Inc. valued side by side against its closest peers. Eloxx Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Eloxx Pharmaceuticals, Inc., and how their positions are changing. At a $54.1M market value, institutional positions materially move Eloxx Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Eloxx Pharmaceuticals, Inc. executives and directors. Shares of Eloxx Pharmaceuticals, Inc. have traded between $0.0000 and $0.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Eloxx Pharmaceuticals, Inc.. Eloxx Pharmaceuticals, Inc. is a $54.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Eloxx Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Eloxx Pharmaceuticals, Inc.. Coverage tracks Eloxx Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.